RxDoctor Payments Data

Michelle Wenzel

Nurse Practitioner · Midland, MINPI 1194423434

Payments from drug & device makers

$1,089in general payments, 2019–2025

Across 55 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kestra Medical Technology Services, Inc.$443
  • Novartis$214
  • Pfizer$165
  • E.r. Squibb & Sons, L.L.C.$86
  • Abiomed$68
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$59
  • plus $54 from 2 others

What the payments were for

  • Food & beverage$1,089100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,089 in reported general payments places this provider in the 80th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$30,839
Medicare patients
477
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban184$214,821
Repatha SureclickEvolocumab67$58,681
FarxigaDapagliflozin Propanediol35$47,809
JardianceEmpagliflozin32$42,185
XareltoRivaroxaban42$37,669
EntrestoSacubitril/Valsartan33$34,877
BrilintaTicagrelor27$21,656
Bisoprolol Fumarate163$5,267
Atorvastatin Calcium326$5,054
Ranolazine ErRanolazine35$4,054
Rosuvastatin Calcium180$3,556
ClopidogrelClopidogrel Bisulfate157$3,091
Metoprolol Succinate232$2,903
Isosorbide Mononitrate ErIsosorbide Mononitrate157$2,769
Ezetimibe80$2,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$214,821184 claims
NovartisEntresto$214$34,87733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Midland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →